Jennifer Jarrett - 23 Jan 2026 Form 4 Insider Report for Arcus Biosciences, Inc. (RCUS)

Role
Chief Operating Officer
Signature
/s/ Carolyn Tang, Attorney-in-Fact
Issuer symbol
RCUS
Transactions as of
23 Jan 2026
Net transactions value
$0
Form type
4
Filing time
26 Jan 2026, 20:21:16 UTC
Previous filing
18 Dec 2025
Next filing
06 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Jarrett Jennifer Chief Operating Officer C/O ARCUS BIOSCIENCES, INC., 3928 POINT EDEN WAY, HAYWARD /s/ Carolyn Tang, Attorney-in-Fact 26 Jan 2026 0001671311

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RCUS Common Stock Award $0 +31,000 +16% $0.000000 224,024 23 Jan 2026 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RCUS Stock Option (right to buy) Award $0 +126,000 $0.000000 126,000 23 Jan 2026 Common Stock 126,000 $22.13 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the grant of restricted stock units that vest in four equal annual installments beginning December 15, 2026, subject to the Reporting Person's continued service to the Company.
F2 Includes the unvested portion of the Reporting Person's RSU grants.
F3 The option becomes exercisable in 48 equal monthly installments after January 1, 2026, subject to the Reporting Person's continued service to the Company.